Previous studies in NSCLC have shown that patients whose tumors presented a high Ki67 labeling index (> 30%) showed a poor prognosis, whereas patients with a low Ki67 index (≤ 30%) on tumor specimens, had a better clinical outcome [43, 44]. Here, MKI67 is linked to neoplasm.